Overall survival of metastatic colorectal cancer patien | Open-i
Bevacizumab More Cost-Effective Than Cetuximab in Metastatic Colorectal Cancer - The ASCO Post
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study | Scientific Reports
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer | NEJM
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Roche - Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Frontiers | Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center | Pharmacology
PLOS ONE: Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). | Semantic Scholar
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
PLOS ONE: Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels | BMC Cancer | Full Text
Overall survival for colorectal cancer patients treated with FOLFIRI®... | Download Scientific Diagram
